|Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children|
JZ Goldenberg, C Yap, L Lytvyn, CKF Lo, J Beardsley, D Mertz, ...
Cochrane Database of Systematic Reviews, 2017
|Adaptive designs in clinical trials: why use them, and how to run and report them|
P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ...
BMC medicine 16 (1), 1-15, 2018
|Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose–volume relationships and role for inverse planning|
LM Tho, M Glegg, J Paterson, C Yap, A MacLeod, M McCabe, ...
International Journal of Radiation Oncology* Biology* Physics 66 (2), 505-513, 2006
|Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial|
C Craddock, N Jilani, S Siddique, C Yap, J Khan, S Nagra, J Ward, ...
Biology of Blood and Marrow Transplantation 22 (2), 385-390, 2016
|Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide|
CN Harrison, AJ Mead, A Panchal, S Fox, C Yap, E Gbandi, A Houlton, ...
Blood, The Journal of the American Society of Hematology 130 (17), 1889-1897, 2017
|Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial|
PN Newsome, R Fox, AL King, D Barton, NN Than, J Moore, C Corbett, ...
The Lancet Gastroenterology & Hepatology 3 (1), 25-36, 2018
|Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single …|
RW Laing, H Mergental, C Yap, A Kirkham, M Whilku, D Barton, ...
BMJ open 7 (11), e017733, 2017
|A comparison of short-term and long-term air pollution exposure associations with mortality in two cohorts in Scotland|
IJ Beverland, GR Cohen, MR Heal, M Carder, C Yap, C Robertson, ...
Environmental health perspectives 120 (9), 1280-1285, 2012
|Development of clinical criteria for functional assessment to predict primary nonfunction of high‐risk livers using normothermic machine perfusion|
H Mergental, BTF Stephenson, RW Laing, AJ Kirkham, DAH Neil, ...
Liver Transplantation 24 (10), 1453-1469, 2018
|Transplantation of discarded livers following viability testing with normothermic machine perfusion|
H Mergental, RW Laing, AJ Kirkham, MTPR Perera, YL Boteon, J Attard, ...
Nature communications 11 (1), 1-12, 2020
|Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia|
C Craddock, D Slade, C De Santo, R Wheat, P Ferguson, A Hodgkinson, ...
Journal of Clinical Oncology 37 (7), 580, 2019
|How to design a dose-finding study using the continual reassessment method|
GM Wheeler, AP Mander, A Bedding, K Brock, V Cornelius, AP Grieve, ...
BMC medical research methodology 19 (1), 1-15, 2019
|Embracing model-based designs for dose-finding trials|
SB Love, S Brown, CJ Weir, C Harbron, C Yap, B Gaschler-Markefski, ...
British journal of cancer 117 (3), 332-339, 2017
|REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of …|
A King, D Barton, HA Beard, N Than, J Moore, C Corbett, J Thomas, ...
BMJ open 5 (3), e007700, 2015
|Examining the sources of occupational stress in an emergency department|
S Basu, C Yap, S Mason
Occupational Medicine 66 (9), 737-742, 2016
|Association between long-term exposure to air pollution and specific causes of mortality in Scotland|
C Yap, IJ Beverland, MR Heal, GR Cohen, C Robertson, DEJ Henderson, ...
Occupational and environmental medicine 69 (12), 916-924, 2012
|Dose transition pathways: the missing link between complex dose-finding designs and simple decision-making|
C Yap, LJ Billingham, YK Cheung, C Craddock, J O'Quigley
Clinical Cancer Research 23 (24), 7440-7447, 2017
|Is there a role for adjuvant hysterectomy after suboptimal concurrent chemoradiation in cervical carcinoma?|
N Walji, AL Chue, C Yap, LJ Rogers, A El-Modir, KK Chan, K Singh, ...
Clinical Oncology 22 (2), 140-146, 2010
|Challenges of clinical trial design for targeted agents against pediatric leukemias|
FJ Mussai, C Yap, C Mitchell, P Kearns
Frontiers in oncology 4, 374, 2015
|Implementing the EffTox dose-finding design in the Matchpoint trial|
K Brock, L Billingham, M Copland, S Siddique, M Sirovica, C Yap
BMC medical research methodology 17 (1), 1-15, 2017